Pharmaceuticals (Mar 2024)

Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease

  • Nejc Piko,
  • Sebastjan Bevc,
  • Radovan Hojs,
  • Robert Ekart

DOI
https://doi.org/10.3390/ph17040418
Journal volume & issue
Vol. 17, no. 4
p. 418

Abstract

Read online

Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Although the prevalence of other complications of diabetes is falling, the number of diabetic patients with end-stage kidney disease in need of kidney replacement therapy is rising. In addition, these patients have extremely high cardiovascular risk. It is more than evident that there is a high unmet treatment need in patients with diabetic kidney disease. Finerenone is a novel nonsteroidal mineralocorticoid receptor antagonist used for treating diabetic kidney disease. It has predominant anti-fibrotic and anti-inflammatory effects and exhibits several renal and cardiac protective effects. This review article summarizes the current knowledge and future prospects of finerenone in treating patients with kidney disease.

Keywords